FDA: Opioid Antidote Naloxone Recalled

Share this content:
FDA: Opioid Antidote Naloxone Recalled
FDA: Opioid Antidote Naloxone Recalled

TUESDAY, June 5, 2018 (HealthDay News) -- A recall of the opioid overdose antidote Naloxone was announced Monday. The U.S. Food and Drug Administration said the recall was triggered by the possibility of "loose particulate matter on the syringe plunger" that could pose a number of health risks, CNN reported.

Those risks include "local irritation, allergic reactions," and a range of cardiovascular issues, including blood clots, according to the FDA. The agency has not received any reports of patient harm from the recalled Naloxone, made by Hospira.

The recall covers single use sterile cartridge units with lot numbers 72680LL and 76510LL in 0.4 mg/mL and 1 mL in 2.5 mL strengths that were distributed to wholesalers, distributors, and hospitals in the United States, Puerto Rico, and Guam between February 2017 and February 2018, CNN reported.

Hospira said distributors and retailers should not use or distribute the recalled Naloxone and should alert stores, pharmacies, and hospitals and others who have received it.

More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Congo Ebola Outbreak Now Second Worst in History

Congo Ebola Outbreak Now Second Worst in History

The worst Ebola outbreak occurred in West Africa in 2014 to 2016

FDA to Resume Inspections of Riskier Foods

FDA to Resume Inspections of Riskier Foods

Agency is bringing back about 150 unpaid employees for the inspections of riskier foods

Breakdown of Blood-Brain Barrier May Drive Dementia

Breakdown of Blood-Brain Barrier May Drive Dementia

Leaky brain capillaries tied to cognitive dysfunction, independent of protein markers for dementia

is free, fast, and customized just for you!




Already a member?

Sign In Now »